^Hengstmann, J. H.; Konen, W; Konen, C; Eichelbaum, M; Dengler, H. J. (1974). “The physiological disposition of p-octopamine in man”. Naunyn-Schmiedeberg's Archives of Pharmacology283 (1): 93-106. doi:10.1007/bf00500148. PMID4277715.
^d’Andrea, Giovanni; Nordera, Gianpietro; Pizzolato, Gilberto; Bolner, Andrea; Colavito, Davide; Flaibani, Raffaella; Leon, Alberta (2010). “Trace amine metabolism in Parkinson's disease: Low circulating levels of octopamine in early disease stages”. Neuroscience Letters469 (3): 348-51. doi:10.1016/j.neulet.2009.12.025. PMID20026245.
^“m-Octopamine, p-octopamine and phenylethanolamine in rat brain: a sensitive, specific assay and the effects of some drugs”. Journal of Neurochemistry29 (6): 1131-5. (December 1977). doi:10.1111/j.1471-4159.1977.tb06519.x. PMID340613.